Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Gepirone hydrochloride, an investigational anxiolytic drug, was found to have at least three polymorphic forms which melted at 180 degrees C (I), 212 degrees C (II), and 200 degrees C (III). Thermal analytical studies showed that forms I and II were an enantiotropic pair, as were forms I and III. Form III was monotropic with form II and there was no temperature at which III was the most stable polymorph. Solubility data from powder dissolution studies were used to estimate a transition temperature of 74 degrees C for the enantiotropic pair of I and II. The difference in enthalpy was 4.5 kcal/mol at 74 degrees C and 2.54 kcal/mol at 25 degrees C. Form I was the most physically stable below 74 degrees C, whereas form II was the most stable above 74 degrees C. Essentially pure samples of I and II could be obtained easily, but pure III could be developed only transiently on the differential scanning calorimeter heating block. Video taping of hot-stage microscopic observations for review was helpful for detecting seed crystals of II or III in samples of I. The information developed is presented in a hypothetical free energy-temperature diagram.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1002/jps.2600741004 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
The preclinical discovery and development of gepirone hydrochloride extended-release tablets: the first oral selective 5-HT1A receptor agonist for the treatment of major depressive disorder.
Expert Opin Drug Discov
September 2025
First Department of Psychiatry, Eginition Hospital, National and Kapodistrian University of Athens, Athens, Greece.
Introduction: Despite advances in antidepressant development, many patients with major depressive disorder (MDD) remain inadequately treated. Gepirone, a selective 5-HT1A agonist without reuptake inhibition, offers a novel mechanism potentially improving efficacy and tolerability over selective serotonin reuptake inhibitors (SSRIs) and earlier agents.
Areas Covered: This case history describes gepirone's discovery and development, including its pharmacodynamic profile, preclinical data on pharmacology, mechanism of action, and effects on depressive-like behavior and anxiety, as well as early clinical findings on its safety and efficacy in major depressive disorder.
Gepirone hydrochloride: a novel antidepressant with 5-HT1A agonistic properties.
Drugs Today (Barc)
July 2019
Pharmacology Research Laboratory, University Institute of Pharmaceutical Sciences, UGC-Centre of Advanced Study, Panjab University, Chandigarh, India.
Article Synopsis
- Depression is a widespread neuropsychiatric disorder impacting over 350 million people globally, with traditional treatments focused on neurotransmission but often leading to adverse side effects like sexual dysfunction.
- Gepirone, a drug in the azapirone class, is being developed to effectively treat major depressive disorder (MDD) and anxiety without the sexual side effects associated with SSRIs, displaying greater selectivity for the 5-HT1A receptor.
- Clinical studies suggest gepirone is promising, showing efficacy and tolerability, with common side effects being mild (nausea, dizziness) and enhanced absorption when taken with food.
Gateways to clinical trials.
Methods Find Exp Clin Pharmacol
May 2005
Department of Pharmacology, Prous Science, Barcelona, Spain.
Article Synopsis
- "Gateways to Clinical Trials" is a comprehensive guide that summarizes recent clinical trials related to various drugs based on current literature and congress findings.
- The data is sourced from the Clinical Trials Knowledge Area of Prous Science Integrity, a drug discovery and development portal.
- This issue highlights a wide range of drugs, including Adalimumab, Bevacizumab, and various other therapeutics used in different medical conditions.
Article Synopsis
- Gateways to Clinical Trials is a comprehensive guide that summarizes the latest clinical trials from current literature and conferences, focusing on various drug developments.
- The data is sourced from Prous Science Integrity's Clinical Trials Knowledge Area, which specializes in drug discovery and development.
- The issue highlights a wide range of drugs, including ABX-IL-8, adalimumab, aripiprazole, and many others, showcasing ongoing research in the pharmaceutical field.
[Review of antidepressants from the TCAs to the third generation drugs].
Neuropsychopharmacol Hung
December 2004
Organon Hungary Kft, Orvosi Osztály, Budapest.
Article Synopsis
- - The paper explores different viewpoints on how unipolar major depressive disorder (MDD) develops and examines available treatment options, especially focusing on various types of antidepressants.
- - It provides a detailed overview of the evolution of antidepressants, from older tri- and tetracyclic drugs to contemporary options like selective serotonin reuptake inhibitors (SSRIs), discussing their pharmacodynamic properties, benefits, and side effects.
- - The review aims to assist psychiatrists in selecting the most effective pharmacological treatments for MDD, while also briefly addressing the advantages and disadvantages of combining different medications.